OBJECTIVES Advances in diagnosis of prostate cancer (PCa)have led to an increased detection of these tumors, some of them with low-risk of progression, with the consequent risk of overdiagnosis and overt treatment. In consequence, there is a tendency to offer alternatives to active therapy, like active surveillance (AS)however, some patients under AS need definitive therapy and after surgery it...

Since the implementation of serum prostate-specific antigen (PSA) as a screening tool revealed acceptable results in reducing prostate cancer specific mortality, demonstrated in the US Prostate, Lung, Colorectal and Ovarian cancer screening trial (PLCO) and the European Randomized Study of Screening for Prostate Cancer (ERSPC), substantial aspects of its utilization should be taken into closer ...

The clinical course of treated or untreated clinically localized adenocarcinoma of the prostate from diagnosis to metastatic progression and finally to death as a result of prostate cancer (PC) varies on the basis of prognostic factors at presentation. In addition, men of PCbearing age often have competing risks for mortality, most notably heart disease, which can significantly shorten their li...

with a power of 0.8 and type I error probability of 0.05. Anyway, in our opinion, metabolic guidance may be rather useful during stereotactic biopsy of parenchymal brain tumors, and may be especially recommended for recurrent, particularly previously irradiated, neoplasms, or for sampling of the highly vascular lesions since in the latter cases, detection of the spectroscopic abnormalities outs...